DexCom, Inc. announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom symposia and presentations at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence. Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its G7 sensor in 16 new markets since ATTD 2023.

The company?s latest sensor, Dexcom ONE+, which was built based on user and HCP feedback and is designed to be easy to use for anyone living with diabetes, has also launched in eight markets within one month of first becoming available. Showing a commitment to not only expanding access to life-changing CGM but also to improving the experience for those already using Dexcom CGM, Dexcom announced that direct to Apple Watch functionality for Apple Watch will have a phased launch available to all G7 iOS users everywhere by the end of the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone.

Peoplechoosing Dexcom G7 to help manage their diabetes will have access to ?direct to Apple Watch? as soon as it launches in their country. With robust clinical evidence and strong partner relationships, Dexcom?s pioneering leadership and capabilities within connected systems remains unparalleled.

Of particular significance within AID systems, the clinically meaningful health outcomes resulting from use of both the Tandem t:slim X2 insulin pump with Control-IQ technology and Insulet Omnipod 5 are only proven when powered by Dexcom CGM. Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024. Data from the longest prospective follow-up study to date of a cohort with established Type 1 diabetes, using the Insulet Omnipod 5 automated insulin delivery system with Dexcom G6, showed that long-term use of the AID system could safely maintain improvements in glycaemic outcomes for up to two years.

Perhaps most significantly, despite the long duration of the study, event rates for severe hypoglycaemia and diabetic ketoacidosis remained low at 2.04 and 0.24 events per 100 person-years. Furthermore, real-world evidence from almost 3,000 people using a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates. Concurrent with these lower rates, on average adult participants spent more than 70% CGM time in range, while paediatric participants achieved 60% CGM time in range.

In December, Dexcom and Tandem announced the connection of Dexcom G7 to Tandem?s t:slim X2 insulin pump software in the USA, swiftly followed by a roll out in markets across Europe, and in both South Africa and New Zealand. The announcement marked a powerful alliance combining Dexcom?s G7 sensor with Tandem?s most widely available pump system. Dexcom also announced the availability, in the USA, of Dexcom G6 with Tandem Mobi, the world?s smallest, durable automated insulin delivery system.Integration with Dexcom G7will quickly follow in the USA in the second quarter of this year.

As demonstrated in multiple symposia and presentations at ATTD this year, clinical evidence continues to build demonstrating the effectiveness of Dexcom CGM use amongst people with all types of diabetes. Of particular note, Dexcom announced a first-of-its-kind study directly linking the benefits of CGM with a reduction in mortality for people treating Type 1 or Type 2 diabetes with insulin?3. These results indicate use of CGM may have broad-based benefits that extend beyond glucose lowering in patients with diabetes on insulin. Dexcom also unveiled new global user data analysis showing clinically meaningful reduction in HbA1c specifically for people managing their Type 2 diabetes with a GLP1 and using a CGM sensor compared to groups not using CGM*4. Dexcom data also showed that amongst Type 2 user populations, the more regularly a Dexcom CGM was worn, the more time a user spent within their desired glucose range5.

Furthermore, a qualitative study involving people treating their Type 2 diabetes with basal insulin found the visualisation of glucose levels offered by Dexcom CGM improved understanding of the impact of treatment and lifestyle decisions on glucose levels, and the impact of those glucose levels on additional health issues.